Alzchem Group AG
F:ACT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Alzchem Group AG
F:ACT
|
DE |
|
A
|
Alzchem Group AG
XMUN:ACT
|
DE |
Earnings Calls
Last Earnings Call
Strong half-year: AlzChem said first-half 2026 revenue rose 6% to almost EUR 304 million and EBITDA rose 14% to EUR 64.5 million, with margins improving to 21.2%.
Specialty Chemicals led: The Specialty Chemicals segment remained the main growth engine, helped by higher volumes, better pricing and strong demand in human nutrition, defense-related applications and custom manufacturing.
Guidance confirmed: Management kept full-year 2026 guidance unchanged at about EUR 600 million of sales and about EUR 126 million of EBITDA, while noting some Q3 sales were pulled forward into the first half.
Expansion on track: The company said major projects in Germany and the U.S. are progressing as planned, including the nitroguanidine expansion, a new guanidine facility and the U.S. site decision at Bushy Park, South Carolina.
Demand mixed: Basics & Intermediates remained weak in agriculture and under pressure from Asian competition, though steel showed early signs of stabilization and management expects improvement in the second half.
Balance sheet strengthened: AlzChem secured a EUR 100 million financing package, which management said supports its growth plans and leaves the company well positioned for future investment.